Rani Shikha, Sehgal Alka, Kaur Jasbinder, Pandher Dilpreet Kaur, Punia Rajpal Singh
Department of Obstetrics and Gynaecology, Dr. BR Ambedkar Institute of Medical Sciences, Mohali, Punjab, India.
Department of Obstetrics and Gynaecology, Government Medical College and Hospital, Chandigarh, India.
J Midlife Health. 2022 Jul-Sep;13(3):200-205. doi: 10.4103/jmh.jmh_52_22. Epub 2023 Jan 14.
Ovarian cancer is associated with high morbidity and mortality. This is due to the nonspecific symptoms and no effective screening methods. Currently, carbohydrate antigen-125 (CA125) is used as a tumor biomarker for the diagnosis of ovarian cancer, but it has its own limitations. Hence, there is a need for other tumor biomarkers for the diagnosis of ovarian cancer. Objective of the study was to evaluate the diagnostic test characteristics of plasma osteopontin (OPN) in detecting ovarian malignancy and comparing its performance with CA125.
This is a prospective cross-sectional diagnostic test evaluation. Women with adnexal mass detected by clinical or radiological examination were enrolled as suspected cases. Women who presented with other gynecological conditions were enrolled as controls. OPN and CA125 levels were measured in all enrolled subjects.
Among 106 women enrolled, 26 were ovarian cancer, 31 had benign ovarian masses, and 49 were controls. Median plasma CA125 levels were higher in subjects with ovarian cancer (298 U/ml; interquartile range [IQR]: 84-1082 U/ml vs. 37.5U/ml; IQR: 17.6-82.9U/ml; < 0.001). CA125 sensitivity, specificity, positive, and negative likelihood ratios were 88.5%, 61.3%, 2.10, and 0.19, respectively. Median plasma OPN levels were higher in subjects with ovarian cancer (63.1 ng/ml; IQR: 39.3-137 ng/ml vs. 27 ng/ml; IQR: 20-52 ng/ml; = 0.001). Sensitivity, specificity, positive, and negative likelihood ratios of OPN were 50%, 87%, 2.58, and 0.62, respectively.
OPN levels were higher in ovarian cancer than in the benign ovarian mass and had better specificity than CA125. OPN can better differentiate between benign and malignant ovarian mass as compared to CA125.
卵巢癌与高发病率和高死亡率相关。这是由于其症状不具特异性且缺乏有效的筛查方法。目前，糖类抗原125（CA125）被用作诊断卵巢癌的肿瘤生物标志物，但它有自身的局限性。因此，需要其他用于诊断卵巢癌的肿瘤生物标志物。本研究的目的是评估血浆骨桥蛋白（OPN）在检测卵巢恶性肿瘤中的诊断测试特征，并将其性能与CA125进行比较。
这是一项前瞻性横断面诊断测试评估。通过临床或放射学检查发现附件包块的女性被纳入疑似病例。患有其他妇科疾病的女性被纳入对照组。对所有纳入的受试者测量OPN和CA125水平。
在纳入的106名女性中，26例为卵巢癌，31例有良性卵巢肿块，49例为对照组。卵巢癌患者的血浆CA125中位数水平更高（298 U/ml；四分位间距[IQR]：84 - 1082 U/ml，而对照组为37.5 U/ml；IQR：17.6 - 82.9 U/ml；P < 0.001）。CA125的敏感性、特异性、阳性和阴性似然比分别为88.5%、61.3%、2.10和0.19。卵巢癌患者的血浆OPN中位数水平更高（63.1 ng/ml；IQR：39.3 - 137 ng/ml，而对照组为27 ng/ml；IQR：20 - 52 ng/ml；P =
0.001）。OPN的敏感性、特异性、阳性和阴性似然比分别为50%、87%、2.58和0.62。
卵巢癌患者的OPN水平高于良性卵巢肿块患者，且特异性优于CA125。与CA125相比，OPN能更好地区分良性和恶性卵巢肿块。
